beta amyloid

Amyloid beta-protein(1-40) Arctic variant (Ab40ARC (E22G)), featuring a glycine at position 22 (Gly22), is a peptide utilized in Alzheimer's disease research [1].

Colivelin is a neuroprotective peptide and activator of STAT3. Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN).

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

Human Serum Albumin (HSA) is the most abundant protein in human plasma, is produced in the liver and is water soluble, with a molecular weight of 66.5 kDa. HSA inhibits Alzheimer's disease by selectively binding to cross-structured A oligomers. HSA is a key endogenous inhibitor of amyloid-β (Αβ) aggregation. HSA is used as a carrier protein in cell culture for the transport of fatty acids, steroids, and thyroid hormones and to regulate osmolality of the blood, and is also used in drug delivery studies, immunoassays, and cell freezing. cell freezing.

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

β-Amyloid (25-35) is a fragment of the Alzheimer’s amyloid beta peptide Aβ(25-35), exhibiting neurotoxic effects and commonly used to establish both cellular and animal models of Alzheimer’s disease.

β-Amyloid (25-35) acetate is the Aβ(25-35) fragment of amyloid beta peptide, exhibiting neurotoxicity and commonly employed in constructing Alzheimer's disease cell and animal models.

Davunetide acetate is derived from activity-dependent neuroprotective protein existing in the mammalian CNS. Davunetide acetate is a microtubule-stabilizing peptide and inhibits Aβ aggregation and Aβ-induced neurotoxicity. Davunetide acetate possesses neuroprotective, neurotrophic, and cognitive protective properties.

neuroprotective peptide that binds to amyloid beta (Aβ)

β-Amyloid (1-37) (human) is potentially associated with mental status in Alzheimer's disease.

The amyloid β-protein is a 39- to 43-amino acid polypeptide that is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's syndrome. Additionally it acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro.

(Rac)-Z-Phe-Phe-FMK (Cathepsin L-IN-2) is a cathepsin L inhibitor that inhibits the tendency of β-amyloid to induce apoptotic changes .

β-Amyloid (1-40), FAM-labeled, is a β-Amyloid (1-40) peptide tagged with a FAM fluorescent label, exhibiting an excitation wavelength (λ ex) of 492 nm and an emission wavelength (λ em) of 518 nm.

β-Amyloid (1-38), derived from mice and rats, is a chemical compound comprising 38 amino acids, specifically residues 1-38 of the Aβ peptide. Notably, it serves as the primary constituent of amyloid plaques associated with Alzheimer's disease.

β-Amyloid (31-35) (β-Amyloid 31-35) is the shortest sequence of native Amyloid-β peptide.

FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium) is a fluorescein isothiocyanate (FITC)-tagged monomeric peptide of amyloid beta 1-42, which plays a critical role in the pathogenesis of Alzheimer’s disease, making FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium) a valuable tool for mechanistic studies, drug screening, and biomolecular investigations related to neurodegenerative processes.

'(Asp37)-Amyloid β-Protein (1-42) [1]' refers to the G37D mutant variant of the wild-type Amyloid-beta (1-42) peptide.

β-Amyloid (1-16) rat is a fragment of the amyloid beta (Abeta) peptide's metal-binding domain, containing three amino acid substitutions compared to its human counterpart, which confer reduced susceptibility to Alzheimer's disease-like neurodegeneration in rats and mice [1].

(Pyr11)-Amyloid β-Protein (11-40) (Aβ11pE-40), a peptide, is utilized in Alzheimer's disease research [1].

β-Amyloid (1-42), human, is a 42-amino acid peptide integral to the pathogenesis of Alzheimer disease.

β-Amyloid 15-21 acetate (Beta-Amyloid (15-21) acetate) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease. This fragment is involved in beta sheet formation.

β-Amyloid (22-35) is a 14-aa peptide, shows aggregates and induces neurotoxicity in the hippocampal cells. Beta amyloid (22-35) is a synthetic truncated fragment of beta-amyloid peptide.

β-Amyloid (1-28), a fragment of the β-Amyloid protein, is involved in metal binding.

Amyloid β-peptide fragment; minimum section required to bind to brain proteins. Binds with high affinity to α7-nicotinic ACh receptors, and impairs memory retention following central administration in mice in vivo.